News | September 27, 2011

New Trial Finds CCTA Superior to MPI for ER Chest Pain Evaluation


September 27, 2011 — A study in the Sept. 27 issue of the Journal of the American College of Cardiology suggests that early coronary computed tomographic angiography (CCTA) is preferable to rest-stress myocardial perfusion imaging (MPI) when evaluating acute low-risk chest pain in the emergency department. The Society of Cardiovascular Computed Tomography conducted the study.

The Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment (CT-STAT) multi-center trial suggests CCTA is faster, more accurate and less costly than MPI.

The study, led by James A. Goldstein, M.D., and Gilbert L. Raff, M.D., of William Beaumont Hospital, Royal Oak, Mich., ran between June 2007 and November 2008. Low-risk patients were randomized to treatment via CCTA or MPI, and followed up over a period of six months.

The two treatments were analyzed primarily over the time taken to diagnose, and also compared over safety (no major adverse cardiac events in patients with normal index tests), and the cost of care to the emergency department.

The results found CCTA patients were diagnosed 54 percent faster than MPI patients, and the total costs of care were 38 percent lower with the CCTA group. This is significant, given that the cost of each MPI test itself was only slightly greater than the cost for each CCTA test.

 Major adverse cardiac events were no different for each diagnostic strategy. The CCTA patients were also exposed to less radiation than the MPI patients (11.5 mSv vs 12.8 mSv, p=0.02).

About 8 million patients in the United States require emergency department evaluation for acute chest pain annually. Currently, extensive testing is required to diagnose or rule out a heart attack in low risk patients without obvious signs. These trial results should have a huge impact in regards to selecting CCTA as a method that is both more efficient and cost-beneficial.

For more information: www.scct.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now